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Recent developments in immuno-oncology demonstrate that not only cancer cells, but also 
features of the tumor microenvironment guide precision medicine. Still, the relationship 
between tumor and microenvironment remains poorly understood. To overcome this limitation 
and identify clinically relevant microenvironmental and cancer features, we applied single-cell 
RNA sequencing to lung adenocarcinomas. While the highly heterogeneous carcinoma cell 
transcriptomes reflected histological grade and activity of relevant oncogenic pathways, our 
analysis revealed two distinct microenvironmental patterns. We identified a prognostically 
unfavorable group of tumors with a microenvironment composed of cancer-associated 
myofibroblasts, exhausted CD8+ T cells, proinflammatory monocyte-derived macrophages 
and plasmacytoid dendritic cells (CEP² pattern) and a prognostically favorable group 
characterized by myeloid dendritic cells, anti-inflammatory monocyte-derived macrophages, 
normal-like myofibroblasts, NK cells and conventional T cells (MAN²C pattern). Our results 
show that single-cell gene expression profiling allows to identify patient subgroups based on 
the tumor microenvironment beyond cancer cell-centric profiling. 
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Lung cancer accounts for the majority of new cases and deaths of cancer worldwide [1]. The 
most common subtype of lung cancer is lung adenocarcinoma, which is at the same time the 
most prevalent subtype in non-smokers [2]. Although some patients can be cured by surgery 
complemented with radiotherapy or chemotherapy, the overall prognosis of lung cancer is still 
poor. Molecular profiling identified a variety of driver mutations and guides treatment with novel 
targeted therapies, such as inhibitors of epidermal growth factor receptor (EGFR) or anaplastic 
lymphoma kinase (ALK) [3, 4]. Moreover, expression of PD-L1 in tumor cells predicts response 
to the recently introduced class of immune checkpoint inhibitors [5]. However, clinical data 
shows that the predictive accuracy of PD-L1 expression alone is limited pointing to more 
complex mechanisms in the relationship between tumor cells and their microenvironment. 
These findings suggest that the classical focus on the tumor cells is not capturing the full 
picture. A more comprehensive characterization including the tumor microenvironment is likely 
required for a better understanding of tumor biology and more precise patient stratifications. 
 Cancers are multicellular communities comprising malignant epithelial cells and 
different types of non-malignant immune and stromal cells which exhibit dynamic and 
reciprocal interactions. Modulation of immune responses, remodeling of the extracellular 
matrix and neoangionesis essentially determine the aggressiveness of cancer [6]. In vitro and 
xenograft studies outline relevant roles for different cell types of the tumor microenvironment. 
Current bulk omics analyses do not allow high-resolution in situ characterization of tumors 
uncovering the cellular diversity of the tumor microenvironment. However, comprehensive 
profiling of tumor microenvironmental cell types and their functional traits in patient tissue is 
essential to estimate the clinical relevance of results from preclinical models.  
In this study, we analyzed tumor epithelial cells and associated non-malignant cells of 
the tumor microenvironment of lung adenocarcinomas. We utilized tissue samples from routine 
lung surgery to generate single-cell libraries using a commercial droplet-based approach and 
investigated gene expression profiles on the single-cell level. This way, we demonstrate high 
interpatient heterogeneity in gene expression of tumor epithelial cells while histological 
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subtypes still share common transcriptomic traits. Within the tumor microenvironment, we 
identified various immune and stromal cell subtypes, of which many were depleted or enriched 
in tumor tissue. Extending previous single-cell studies [7-10], we found that the heterogeneous 
cellular composition of the tumor microenvironment across patients follows specific patterns 
that were associated with the differentiation grade of carcinoma cells. We evaluated these 
signatures in an independent retrospective cohort characterized by bulk gene expression 
profiling and found that these patterns might correlate with patient prognosis. We conclude that 
a comprehensive profiling of lung adenocarcinomas considering the cellular diversity of tumor-
associated non-malignant cells may help reveal novel tumor subtypes based on carcinoma 
cells but also microenvironmental features, and provide clinically relevant information guiding 
novel therapies targeting components of the tumor microenvironment. 
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Single-cell RNA sequencing uncovers the cellular diversity of lung adenocarcinomas 
To study the cellular composition of lung adenocarcinomas with a particular focus on the 
microenvironment on the single-cell level, 10 normal lung and 10 lung adenocarcinoma fresh 
tissue samples were collected during routine lung surgery. Evaluation of consecutive H&E 
stained tissue sections ensured proper sampling of tumor tissue and showed that tumor 
morphology ranged from well differentiated lepidic to poorly differentiated sarcomatoid growth 
patterns (Supp. Fig. 1). Tissue samples were enzymatically dissociated to a single-cell 
suspension to produce single-cell transcriptome libraries using a commercial droplet-based 
system (Fig. 1A). Unsorted single-cell RNA sequencing yielded in 133,736 single-cell 
transcriptomes of which 114,489 high-quality transcriptomes remained after quality control and 
filtering (for quality control parameters see Supp. Fig. 2). 
Analysis and visualization by Uniform Manifold Approximation and Projection (UMAP) 
[11] showed that single-cell transcriptomes of different tissue types or patients both 
intermingled in many clusters, excluding general batch effects, and partly formed tumor- or 
patient-specific clusters, indicating underlying biological differences (Fig. 1B-C). To uncover 
which cellular compartments account most for interpatient variability, we analyzed single-cell 
transcriptomes for the expression of epithelial, immune and stromal marker genes. In total, 
20,450 epithelial, 89,766 immune, and 4,273 stromal single-cell transcriptomes were covered, 
suggesting an overrepresentation of immune cell transcriptomes as observed in other studies 
[9, 12]. The yield of epithelial transcriptomes varied depending on histological subtypes, as we 
observed less than 10% in solid/sarcomatoid, but up to >40% in lepidic/acinar carcinomas (Fig. 
1D). Epithelial cells showed the highest degrees of interpatient heterogeneity (Fig. 1C-D). 
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Figure 1: Single-cell RNA sequencing of lung adenocarcinomas 
(A) Schematic representation of the workflow, 10 normal (blue) and 10 tumor (red) tissue samples were 
obtained from 12 patients. (B+C) UMAPs based on the top 15 principal components of all single-cell 
transcriptomes after filtering, color-coded by (B) tissue type, or (C) patient. (D) Overview of clinical 
features, clinically relevant oncogenic mutations and gene fusions; quantification of main cell types per 
patient and UMAP of all single-cell transcriptomes color-coded by main cell type. 
 
Intertumoral heterogeneity of tumor epithelial cells reflects differentiation gradients 
To further dissect interpatient variability within the epithelial cell compartment, epithelial single-
cell transcriptomes were subset and reclustered (Supp. Fig. 3A). Epithelial clusters 
overrepresented in normal or tumor tissue samples were defined as normal or tumor cell 
clusters, respectively (Supp. Fig. 3B). Within the normal cell clusters, we found alveolar type 1 
and 2, club, ciliated, and even a small cluster of neuroendocrine cells (Fig. 2A), which were 
characterized by expression of typical individual marker genes (Fig. 2B) and gene signatures 
(Supp. Fig. 4A-B) [13, 14]. The club cell cluster also expressed basal cell marker genes such 
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as NGFR and KRT5 indicating an admixture of small amounts of basal cells in this cluster (Fig. 
2B). Few single-cell transcriptomes of normal epithelial cell types were also obtained from 
tumor tissue samples (Fig. 2A), probably due to normal tissue adjacent to or entrapped within 
the tumor. Beyond that, tumor cell clusters distinctly segregated from the normal cell clusters 
(Fig. 2A). In contrast to normal cell clusters, the tumor cell clusters were mainly patient-specific, 
indicating high intertumoral heterogeneity of tumor epithelial cells (Fig. 2A). This was 
underlined by a variety of genes differentially expressed across tumors such as EGFR, TFF3, 
CDKN2A, and SFTPA2 (Fig. 2C, black arrowheads), correlating with protein expression as 
shown by immune staining (Fig. 2D). In order to analyze functional intertumoral heterogeneity, 
we inferred the activity of potentially oncogenic signaling pathways from single-cell gene 
expression profiles [15, 16]. We found highly varying pathway activity scores for EGFR, TGFβ, 
JAK/STAT, Hypoxia, and PI3K signaling in tumor epithelial cells of different patients (Fig. 2E), 
and these patterns were largely unrelated to the mitotic activity of tumor epithelial cells (Supp. 
Fig. 3D). The activity of p53 signaling was significantly reduced in tumors harboring TP53 
mutations, demonstrating the functional effects of genomic alterations. In contrast, pathway 
activity scores for EGFR and MAPK signaling were not significantly higher in KRAS-mutated 
compared to KRAS-wildtype tumors, suggesting that other mechanisms can activate MAPK in 
cancer (Supp. Fig. 3C). Taken together, tumor epithelial cells exhibited high intertumoral 
heterogeneity on the levels of gene expression, protein expression and signaling pathway 
activity. 
Despite obvious intertumoral heterogeneity of tumor epithelial cells, we also noted 
shared features of tumor transcriptomes across patients. Some differentially expressed genes 
were strongly expressed in more than one tumor cases such as SCGB3A1 in patients P018, 
P031 and P032, and SCGB3A2 in P018 and P032 (Fig. 2C, white arrowheads). Additionally, 
tumors shared signaling pathway activity patterns. Pathway activity scores for EGFR, TGFβ 
and JAK/STAT signaling were high in tumors of patients P030, P033 and P034, while the 
highest PI3K signaling activity was found in P018 and P032 (Fig. 2E). In order to emphasize 
similarities between tumors from different patients, we performed UMAP embedding based on 
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fewer principal components (4, 6, 8 instead of 20). In low-dimensional UMAPs, tumor cells 
clustered less by patient, but rather by histological subtypes (Supp. Fig. 3E). Here, the first 
principal component (PC1) displayed a gradient from poorly and moderately (sarcomatoid, 
solid, papillary, mucinuous) to moderately (acinar) to well differentiated tumors (lepidic) (Fig. 
2F, Supp. Fig. 3E+G). Interestingly, SCGB3A1 and SCGB3A2, two genes that were previously 
associated with lung development [17], positively correlated with this dimension (Supp. Fig. 
3F, arrowheads). Moreover, gene signature scores of normal lung cell types [13] along PC1 
showed a strong positive correlation with gene expression profiles of alveolar type 1 and 2 as 
well as club cells (Fig. 2G). Together, this indicates that PC1 reflects the degree of 
differentiation of tumor epithelial cells. Hence, the top 30 genes positively and negatively 
correlated with PC1 were defined as an “alveolar/club-like” and “undifferentiated” tumor cell 
signature, respectively (Fig. 2F-H, Supp. Fig. 3I).  
To further characterize functional features of “alveolar/club-like” and “undifferentiated” 
tumor epithelial cells, we analyzed mitotic and pathway activity along PC1. While tumor cells 
with different degrees of differentiation exhibited no clear differences in mitotic activity (Supp. 
Fig. 3H), we found high pathway activity scores for JAK/STAT, Hypoxia, EGFR and TGFβ 
signaling in “undifferentiated”, and high scores for PI3K signaling in “alveolar/club cell-like” 
tumor epithelial cells, respectively (Fig. 2H). We conclude that tumor epithelial cells of different 
lung adenocarcinoma patients exhibit transcriptional patterns along a spectrum ranging from 
undifferentiated to differentiated alveolar/club cell-like phenotypes that correlate with distinct 
oncogenic pathway activity. 
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Figure 2: Intertumoral heterogeneity of tumor epithelial cells in lung adenocarcinomas 
(A) UMAPs based on the top 20 principal components of all epithelial single-cell transcriptomes color-
coded by tissue type, cell type and patient, and quantification of epithelial cell types per tissue type, AT1 
= alveolar type 1 cells, AT2 = alveolar type 2 cells. (B) Average gene expression of selected marker 
genes for normal epithelial cell types. (C) Differentially expressed genes in tumor epithelial cells grouped 
by patients, maximum top 10 genes showed per patient, for patient color code see (A). (D) 
Immunohistochemical staining of proteins encoded by selected differentially expressed genes indicated 
by black arrowheads in (C). (E) Mean pathway activity scores of tumor epithelial cells grouped by patient. 
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(F) Distribution of histological subtypes, (G) mean module scores of normal epithelial cell type gene 
signatures, and (H) mean pathway activity scores of tumor epithelial cells sorted along principal 
component 1 (PC1). (F+G+H) Principal component analysis based on gene expression of all tumor 
epithelial single-cell transcriptomes; schematic depiction of tumor cell signature module scores along 
PC1. 
 
Two subtypes of myofibroblasts constitute the tumor stromal microenvironment  
Neovascularization and remodeling of the extracellular matrix impacts on tumor growth and 
metastasis. To analyze the cellular composition of the stromal microenvironment, we 
separately analyzed stromal cells from both normal and tumor tissue samples. We identified 
different clusters of endothelial and lymphatic endothelial cells, different clusters of fibroblasts, 
myofibroblasts and smooth muscle cells, as well as mesothelial cells (Fig. 3A, for normal tissue 
per patient see Supp. Fig. 5A) which were characterized by expression of typical marker genes 
(Fig. 3B) and gene signatures (Supp. Fig. 4A-B) [13, 14]. Among the endothelial cells clusters, 
tumor tissues were dominated by clusters 2 and 4 (Fig. 3A). These clusters showed high 
expression of genes involved in angiogenesis such as VWA1 and HSPG2, as well as high 
expression of INSR, encoding a marker protein and possible therapeutic target in tumor-
associated endothelial cells, consistent with a previous report [9] (Supp. Fig. 5B, arrowheads). 
While the proportion of smooth muscle and mesothelial cell clusters did not differ significantly 
between normal and tumor tissues, we detected a shift from fibroblast to myofibroblast cell 
clusters in tumor tissues (Fig. 3A). Here, myofibroblast clusters were characterized by 
expression of both fibroblastic marker genes, such as PDGFRA and LUM, and smooth muscle 
marker genes, such as MYLK and ACTA2 (Fig. 3B). Hence, besides tumor-associated 
endothelial cells, myofibroblasts characterized the stromal microenvironment of lung 
adenocarcinomas. 
Notably, myofibroblast cluster 2 was almost exclusively found in tumor tissues while 
myofibroblast cluster 1 occurred in both normal and tumor tissues. In myofibroblast cluster 2, 
differential gene expression analysis revealed high expression of collagens such as COL3A1, 
COL5A1, COL5A2 and COL6A3, other matrix proteins such as VCAN, as well as matrix-
degrading enzymes such as SULF1 and MMP11, suggesting that these cells are involved in 
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remodeling of the extracellular matrix of the tumor microenvironment (Fig. 3C, arrowheads). 
Myofibroblast cluster 2 was also characterized by high activity of TGFβ and JAK/STAT 
signaling as well as hypoxia-induced pathways (Fig. 3D), which are common features of 
cancer-associated myofibroblasts [18, 19]. In contrast, myofibroblast cluster 1 exhibited low 
activity scores of all of these pathways. The relative proportion of myofibroblast clusters 1 and 
2 within the fibroblastic/muscle cell compartment correlated inversely across patients (Fig. 3E). 
We conclude that myofibroblasts cluster 1 and 2 represent “normal-like” and “cancer-
associated” phenotypes of myofibroblasts, respectively. Moreover, our results suggest tumor 
subtypes where the tumor stromal microenvironment is predominated by either “normal-like” 
or “cancer-associated” myofibroblasts. 
 
Figure 3: Composition of the stromal microenvironment of lung adenocarcinomas 
(A) UMAPs based on the top 20 principal components of all stromal single-cell transcriptomes split by 
tissue type, color-coded by cell cluster; and relative quantification of endothelial and fibroblastic/muscle 
cell clusters per tissue type and, for tumor samples, per patient. (B) Average gene expression of selected 
marker genes for stromal cell clusters, for cell cluster color code see (A). (C) Differentially expressed 
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genes of fibroblastic/muscle cell clusters, maximum top 10 genes showed per cell cluster, for cell cluster 
color code see (A), black arrowheads indicate relevant marker genes of myofibroblast cluster 2 
mentioned in the main text. (D) Mean pathway activity scores of different fibroblastic/muscle cell clusters, 
mesothelial cells excluded, black arrowheads indicate relevant pathways of myofibroblast clusters 1 and 
2 mentioned in the main text. (E) Correlation of the relative quantity of myofibroblast clusters 1 and 2, 
color-coded by patient; Spearman’s correlation statistics, linear regression line. 
 
The tumor immune microenvironment exhibits pro- and anti-inflammatory traits 
We next analyzed immune cells of the tumor microenvironment, as above, to uncover potential 
roles in both promotion and suppression of tumor growth. We identified different clusters of 
tissue-resident and monocyte-derived macrophages, monocytes, myeloid and plasmacytoid 
dendritic cells, mast cells, different clusters of T, NK, B and plasma cells (Fig. 4A, for normal 
tissue per patient see Supp. Fig. 6A) based on typical marker genes (Fig. 4B) and gene 
signatures (Supp. Fig. 4A-B) [13, 14]. Although single-cell transcriptomes of most cell clusters 
were found in both normal and tumor tissue samples, we noted distinct quantitative shifts in 
the cellular composition of the tumor immune microenvironment. 
Among the myeloid cells in tumor tissue samples, we observed an increase in myeloid 
and plasmacytoid dendritic cells, while monocytes were decreased. Moreover, we found a 
decrease in tissue-resident and an increase in monocyte-derived macrophages in the tumor 
samples (Fig. 4A). In addition to conventional macrophage markers, monocyte-derived 
macrophages were characterized by expression of CD14, CSF1R and LGMN [20, 21] (Fig. 
4B). Among monocyte-derived macrophages, we identified five clusters, of which clusters 1 
and 2 clearly predominated the myeloid cell compartment. Here, cluster 2 expressed high 
levels of proinflammatory chemokines such as CXCL9 and CXCL10 and the proinflammatory 
cytokine IL1B (Supp. Fig. 6B, arrowheads). Correspondingly, cluster 2 exhibited high 
expression scores of gene signatures related to immune response and M1 polarization [22, 
23] (Fig. 4C, black arrowheads). In contrast, cluster 1 showed high expression of SELENOP 
(Supp. Fig. 6B, arrowhead), which has been related to M2 polarization of tumor-associated 
macrophages [24], and low scores of immune response-related signatures (Fig. 4C, white 
arrowheads). This indicates that monocyte-derived macrophage clusters 1 and 2 represent 
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more anti- and pro-inflammatory functional states, respectively. Notably, the anti- and 
proinflammatory monocyte-derived macrophage clusters differed between tumor cases (Fig. 
4A). The tumor immune microenvironment of some tumors was dominated by the 
proinflammatory cluster 2 (P023, P027, P030, P034), while in other patients we found 
predominantly anti-inflammatory cluster 1, or only few monocyte-derived macrophages at all 
(Fig. 4D). In addition, the proportion of proinflammatory monocyte-derived macrophages 
cluster 2 correlated with the occurrence of other myeloid cell types such as plasmacytoid 
dendritic cells (Fig. 4D), pointing at distinct cellular patterns of the myeloid compartment of the 
tumor immune microenvironment. 
Within the lymphoid cell compartment, NK and conventional T cells were decreased, 
while CD8+ T, B and plasma cells were increased in tumor tissues. In addition, regulatory T 
cells were almost exclusively found in tumor tissue samples (Fig. 4A). Regulatory T cells 
expressed inhibitory molecules such as CTLA4 and TIGIT (Supp. Fig. 6C, arrowheads) 
corresponding to their role in autoimmune tolerance under physiological conditions and 
immunosuppression in the tumor microenvironment [25]. We identified in total four clusters of 
CD8+ T cells. Here, we observed a shift from cluster 3 in normal tissues to clusters 1 and 2 
and proliferating CD8+ T cells in tumor tissues (Fig. 4A). While all CD8+ T cell clusters showed 
high expression scores of a gene signature related to cytotoxicity [10], expression scores of 
an exhaustion signature [10] were only high in the tumor-enriched CD8+ T cell clusters 1 and 
2 and proliferating CD8+ T cells (Fig. 4E, black arrowheads), but not in the normal-enriched 
CD8+ T cell cluster 3 (Fig. 4E, white arrowhead). The abundance of exhausted CD8+ T cells 
showed a trend towards positive correlation with the proportion of regulatory T cells, while we 
found a significant positive correlation with proinflammatory monocyte-derived macrophages 
(cluster 2) and plasmacytoid dendritic cells. 
Taken together, we found patient-overarching changes of the tumor immune 
microenvironment of lung adenocarcinomas such as a shift from tissue-resident to monocyte-
derived macrophages and an enrichment in regulatory T cells and exhausted CD8+ T cells. 
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Moreover, our results suggest that interpatient heterogeneity is not restricted to epithelial 
cancer cells but also reflected by distinct tumor immune microenvironment patterns. 
 
Figure 4: Composition of the immune microenvironment of lung adenocarcinomas 
(A) UMAPs based on the top 20 principal components of all immune single-cell transcriptomes split by 
tissue type, color-coded by cell cluster; and relative quantification of myeloid and lymphoid cell clusters 
per tissue type and, for tumor samples, per patient. (B) Average gene expression of selected marker 
genes for immune cell clusters, for cell cluster color code see (A). (C) Module scores of gene signatures 
related to inflammation and M1/M2 polarization of different macrophage clusters, white and black 
arrowheads indicate monocyte-derived macrophage clusters 1 and 2, respectively, for cell cluster color 
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code see (A). (D) Correlation of the relative quantity of selected myeloid immune cell clusters, color-
coded by patient, for patient color code see (F); Spearman’s correlation statistics, linear regression line. 
(E) Module scores of gene signatures related to cytotoxicity and exhaustion of different CD8+ T cell 
clusters, white and black arrowheads indicate cell clusters enriched in normal or tumor tissue, 
respectively, for cell cluster color code see (A). (F) Correlation of the relative quantity of selected 
lymphoid and myeloid immune cell clusters, color-coded by patient; Spearman’s correlation statistics, 
linear regression line.  
 
The tumor microenvironment of lung adenocarcinoma features two major patterns 
To integrate our analyses of variable cell prevalences in the tumor microenvironment, we 
calculated proportions of cells of the myeloid, lymphoid, endothelial and fibroblastic/muscle cell 
compartments across patients (for cell counts see Supplementary Tables 1-4). Principal 
component analysis showed that tumors formed subgroups based on the cellular composition 
of the tumor microenvironment (Fig. 5A). One group of tumors (P018, P019, P024, P031, P032 
and P033) was marked by anti-inflammatory monocyte-derived macrophages, NK cells, 
conventional T cells, myeloid dendritic cells, and normal-like myofibroblasts (referred to as 
MAN²C pattern, Fig. 5B), while a second group of tumors (P023, P027, P030 and P034) was 
characterized by proinflammatory monocyte-derived macrophages, exhausted CD8+ T cells, 
plasmacytoid dendritic cells, and cancer-associated myofibroblasts (referred to as CEP² 
pattern, Fig. 5B). In particular for cell types distinctive of the CEP² pattern, we found many 
positive correlations of cell type abundances in the tumor microenvironment (Fig. 5C, Supp. 
Fig. 7A). Furthermore, the two groups based on composition of the microenvironment also 
largely separated histologically well and moderately differentiated tumors from more poorly 
differentiated tumors (Fig. 5A). This was also reflected by mean expression scores of the 
“alveolar/club-like” or “undifferentiated” tumor cell signatures, respectively (Fig. 5B). These 
results illustrate that lung adenocarcinomas harbor two distinct tumor microenvironment 
patterns, termed MAN²C and CEP², correlating with high and low tumor differentiation grade, 
respectively. 
To test if these tumor microenvironmental expression patterns can be recapitulated in 
larger patient cohorts, we analyzed bulk gene expression data of The Cancer Genome Atlas 
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(TCGA) lung adenocarcinoma cohort. Expression of cell type signatures identified by single-
cell RNA sequencing was quantified in the bulk data by single-sample gene set enrichment 
analysis (ssGSEA) [26] (for marker genes see Supplementary Tables 5-8). We found a specific 
positive correlation of the alveolar/club-like tumor cell signature with anti-inflammatory 
monocyte-derived macrophages and normal-like myofibroblasts, recapitulating the MAN²C 
pattern, and, on the other hand, a positive correlation of the undifferentiated tumor cell 
signature with proinflammatory monocyte-derived macrophages and cancer-associated 
myofibroblasts, recapitulating the CEP² pattern (Fig. 5D, Supp. Fig. 7B). Hence, we were able 
to recapitulate in a large cohort the distribution of macrophage and myofibroblast subtypes of 
the tumor microenvironment patterns revealed by single-cell RNA sequencing, although 
analysis of bulk data may miss scarce cell types and is likely to be influenced by relative sizes 
of the immune or stromal compartments in the bulk samples. 
To investigate the biological and clinical relevance of these patient subgroups, we 
analyzed the overall survival of the TCGA lung adenocarcinoma cohort contigent on the 
different gene signatures of tumor epithelial cells, monocyte-derived macrophages and 
myofibroblasts. Since our single-cell analyses revealed that alveolar/club-like and 
undifferentiated tumor cells, anti- and pro-inflammatory macrophages, and normal-like and 
cancer-associated myofibroblasts were inversely correlated, respectively, we used the ratio of 
corresponding signatures to stratify patients. Gene signatures representing the MAN²C 
pattern, that is alveolar/club-like tumor cells, anti-inflammatory monocyte-derived 
macrophages and normal-like myofibroblasts, were associated with a better overall survival 
compared to the CEP² pattern, represented by gene signatures of undifferentiated tumor cells, 
pro-inflammatory monocyte-derived macrophages and cancer-associated myofibroblasts (Fig. 
5E). This association was confirmed in univariate analyses for all signatures (tumor cell 
signatures: HR 0.10, 95%CI 0.03-0.26, p < 0.001, myofibroblast signatures: HR 0.08, 95%CI 
0.02-0.28, p < 0.001, macrophage signatures: HR 0.14, 95%CI 0.02-0.94, p = 0.043) and in 
multivariate analyses for the tumor cell signatures (HR 0.13, 95%CI 0.03-0.56, p < 0.001), 
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hinting at a potential clinical relevance of the MAN²C and CEP² patterns in lung 
adenocarcinoma.  
In summary, our results show that lung adenocarcinomas can be stratified into clinically 
relevant subgroups which are not only characterized by the grade of tumor epithelial cells, but 
also by the cellular composition of their associated tumor microenvironment (Fig. 5F). We 
therefore propose two major microenvironmental patterns in lung adenocarcinoma which we 
term MAN²C and CEP² according to the initial letters of the respective characteristic cell types. 
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Figure 5: Tumor microenvironmental patterns in lung adenocarcinomas 
(A) Principal component analysis based on the proportion of stromal and immune cell clusters, color-
coded by histological subtype, patients indicated. (B) Normalized proportion of stromal and immune cell 
clusters, mean module scores of tumor cell signature, and histological subtypes per patient, patients 
sorted along the first principal component from principal component analysis in (A), cell clusters included 
in the model in (F) in bold. (C) Correlation of the proportion of stromal and immune cell clusters, most 
connected section of correlation network plot shown; Spearman’s correlation statistics, only correlations 
with rho > 0.7 and p < 0.05 shown. (A+B+C) Cell clusters occurring in less than 3 patients were excluded 
from analyses. (D) Correlation of single-sample gene set enrichment analysis (ssGSEA) enrichment 
scores of 533 patients from the TCGA lung adenocarcinoma cohort based on marker genes of selected 
immune and stromal cell subtypes and tumor cell signatures; Spearman’s correlation statistics, linear 
regression line. (E) Kaplan-Meier overall survival curves of 524 patients from the TCGA lung 
adenocarcinoma cohort grouped by ratios of ssGSEA enrichment scores for selected immune and 
stromal cell subtypes or tumor cell signatures; log-rank statistics, univariate Cox regression. (F) 
Schematic representation of subtypes of lung adenocarcinoma characterized by different grades of 
tumor epithelial cell differentiation and different composition of the corresponding tumor 
microenvironment.  
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By applying single-cell RNA sequencing to lung adenocarcinomas, we identified different cell 
types enriched in the tumor microenvironment such as myofibroblasts, monocyte-derived 
macrophages, dendritic cells, regulatory T cells and exhausted CD8+ T cells, and observed a 
high interpatient heterogeneity with respect to their distribution. This led us to identify two major 
microenvironmental patterns: i) a rather normal-like tumor microenvironment characterized by 
normal-like myofibroblasts, conventional T cells, NK cells, but also anti-inflammatory 
monocyte-derived macrophages and myeloid dendritic cells, referred to as MAN²C pattern, 
and ii) a more distinctly altered tumor microenvironment characterized by proinflammatory 
monocyte-derived macrophages, plasmacytoid dendritic cells, exhausted CD8+ T cells and 
cancer-associated myofibroblasts, referred to as CEP² pattern (Fig. 5F). Here, the MAN²C 
pattern was associated with an alveolar/club-like gene expression pattern of carcinoma cells, 
lower histological grade and better prognosis, while the CEP² pattern was associated with an 
undifferentiated gene expression pattern of carcinoma cells, higher histological grade and 
worse prognosis. 
Currently, besides tumor stage, histological grading based solely on the predominant 
tumor growth pattern is used to predict prognosis in lung adenocarcinoma. However, in 
particular for intermediate grade tumors, a more precise risk stratification is needed [27]. 
Different histological features, including nuclear grade, mitotic count, and tumor budding [27], 
as well as a combined histological grading taking into account intertumoral heterogeneity [28] 
have been proposed. However, these concepts focus on the carcinoma cells and do not 
include potentially prognostically relevant features of the complex composition of the tumor 
microenvironment. Most available data focus on single cell types such as tumor-associated 
macrophages. Although evidence points to a positive prognostic effect of pro-inflammatory 
tumor-associated macrophages (M1 macrophages), results from many studies are 
inconclusive which might be due to the fact that differentiation between macrophage subtypes 
based on a limited number of immunohistochemical markers is not straightforward [29]. Our 
results suggest that the microenvironmental CEP² pattern is associated with worse prognosis. 
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While this contradicts some previous works with regard to pro-inflammatory tumor-associated 
macrophages [29], it is in line with existing evidence for cancer-associated myofibroblasts [30] 
and plasmacytoid dendritic cells [31]. The absence of cancer-associated myofibroblasts, and 
the presence of NK cells [32] and conventional T cells [33] support the association of the 
MAN²C pattern with better prognosis. In contrast to recent evaluations of the tumor 
microenvironment by bulk gene expression profiling [34-36], our analysis proposes novel 
microenvironmental signatures by comprehensive in-depth characterization of different 
immune and stromal cells complementing the carcinoma cell-centric view. 
As immune cells have already been shown to have predictive value underlined by the 
introduction of immune checkpoint inhibitors and the evaluation of PD-L1 expression in some 
cancers (although not yet lung cancer [37]), it is likely that more comprehensive 
characterizations of the immune tumor microenvironment will provide even deeper insights in 
patient stratification and drug development. Recently, expression of the proinflammatory 
cytokines CXCL9 and CXCL10 by tumor-associated macrophages, for instance, has been 
shown to be essential for tumor response to anti-PD-L1 therapy [38, 39]. Interestingly, we 
observed high expression of these cytokines in pro-inflammatory monocyte-derived 
macrophages indicating that the microenvironmental CEP² pattern, which was also marked by 
exhausted CD8+ T cells, could be a predictor of response to anti-PD-L1 therapy. In addition, 
the CEP² pattern was characterized by cancer-associated myofibroblasts which showed high 
expression of potential novel therapeutic targets, such as PSTN and MMP11 [40, 41]. Despite 
an overall depletion of NK cells in tumors in agreement with other studies [7, 9], the MAN²C 
microenvironmental pattern still contained small populations of NK cells which could be 
targeted by immunostimulatory agents [42]. Although not specifically related to the MAN²C or 
CEP² pattern, we and others [8, 9] observed an enrichment of B cells in some tumors with 
potential importance in development of novel immunotherapies [43]. 
 While the analysis of the tumor microenvironment will likely benefit from single cell 
approaches most substantially because of its complex cellular composition, they will also 
contribute to a better understanding of the tumor itself because lung cancers are characterized 
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by high tumor mutational burden [44] and high genomic intertumoral heterogeneity [45]. On 
the transcriptional level, differences have been described between squamous and 
adenocarcinomas of the lung [46], while this is less evident for histological subtypes of lung 
adenocarcinoma [47]. Interestingly, despite intertumoral heterogeneity, we found that single-
cell transcriptomes of tumor epithelial cells retained similarities across patients corresponding 
to the established histological subtypes of lung adenocarcinoma [27]. We defined two inversely 
correlated tumor cell signatures, “alveolar/club-like” and “undifferentiated”, reflecting a 
transcriptional differentiation gradient reminiscent of transcriptional patterns, recently 
described by Kim and colleagues [9]. Furthermore, the “undifferentiated” tumor cell signature 
was associated with high EGFR signaling, being already a therapeutic target in KRAS-wildtype 
lung adenocarcinomas [4], and JAK/STAT signaling, which is a possible therapeutic target in 
preclinical KRAS-mutant tumor models [48]. The “alveolar/club-like” tumor cell signature 
correlated with high PI3K pathway activity, which has been under early clinical investigation as 
therapeutic target, however, with yet unconvincing results, possibly due to insufficient 
molecular characterization and selection of patients [49]. 
Our findings show that single cell approaches contribute to a better understanding of 
the heterogeneity within each tumor tissue compartment, but may also prove invaluable for 
analysing the complex interactions between malignant epithelial cells and various non-
malignant stromal and immune cells. In our study, we identified two major tumor 
microenvironmental patterns associated with tumor differentiation grade, termed MAN²C and 
CEP², with the potential to predict prognosis, therapy response and provide insight on possible 
novel therapeutic targets. Nevertheless, the relevance of our proposed tumor 
microenvironmental subtypes will have to be validated in larger clinical cohorts. Moreover, the 
question of cause and consequence remains open: To which extent do cancer cells shape 
their microenvironment or does the microenvironment affect cancer cells? Given the cellular 
diversity of the tumor microenvironment, many possible cellular interactions have been studied 
in preclinical models. These preclinical efforts need to be complemented by translational 
studies to identify critical mechanisms in this complex network that determine tumor response 
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to targeted or immune therapies in the clinical context. While our study demonstrates how 
single-cell gene expression profiling of clinical samples can contribute to this task, in the future, 
other single-cell approaches comprising spatial information [50], surface protein expression 
[51] and epigenetic characterization [52] will help to complete the picture [53].  
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Collection of tissue specimens  
Fresh normal lung parenchyma and tumor tissues were obtained from previously untreated 
lung adenocarcinoma patients undergoing primary surgery during intraoperative pathologist 
consultation. All patients were aware of the planned research and agreed to the use of tissue. 
Research was approved by vote EA4/164/19 of the ethics committee of Charité - 
Universitätsmedizin Berlin. 
Tissue dissociation and single cell isolation 
Tissue specimens of approximately 0.1-0.5 cm³ were stored short-term (maximum 3 hours) on 
ice in Tissue Storage Solution (Miltenyi, 130-100-008) for transport. Next, tissues were minced 
using two scalpels and dissociated using the Tumor Dissociation Kit, human (Miltenyi, 130-
095-929) and a gentleMACS Octo Dissociator with heaters (Miltenyi, 130-096-427), using 
program 37C_h_TDK_1 for 30-45 min. Cell suspensions were filtered using 100 µm filters, and 
all subsequent steps were performed at 4°C or on ice. Cells were pelleted by centrifugation at 
300 g for 5 min in BSA-coated low-binding tubes, and cells were treated with 1 ml ACK 
erythrocyte lysis buffer for 60 seconds and washed with DMEM. Cells were pelleted, 
resuspended in PBS, cell suspensions were filtered using 20 µm filters, debris was removed 
using the Debris Removal Solution (Miltenyi, 130-109-398), and cells were counted using a 
Neubauer chamber. 
Single-cell RNA sequencing 
10,000 single cells were used for single-cell library production, using the Chromium Single Cell 
3´Reagent Kit v3 and the Chromium Controller (10x Genomics) according to the 
manufacturer’s protocol. Libraries were sequenced on a HiSeq 4000 Sequencer (Illumina) at 
100-400 mio. reads per library to a mean library saturation of 55% resulting in average 54,000 
reads per cell. 
H&E and immunostaining 
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3-5 µm tissue sections formalin-fixed and paraffin-embedded (FFPE) tissue were used for 
immunofluorescence, immunohistochemistry and hematoxylin and eosin (H&E) staining.  
For H&E staining, sections were stained for 8 min in acidic haemalum staining solution 
(Waldeck) and for 2,5 min in eosin staining solution (Sigma-Aldrich) at room temperature using 
a Tissue-Tek Prisma Plus slide stainer (Sakura). 
Immunohistochemical and immunofluorescence stainings of FFPE tissue sections were 
performed on the BenchMark XT immunostainer (Ventana Medical Systems). For antigen 
retrieval, tissue sections were incubated in CC1 or CC2 buffer (both Ventana Medical Systems) 
for 30 min at 100°C. Sections were incubated with primary antibodies for 60 min and with 
secondary antibodies for 30 minutes at room temperature diluted in Dako Real Antibody 
Diluent (Dako, S2022). The following primary antibodies were used: rabbit anti-TFF3 (Abcam, 
ab108599, 1:250, CC1 antigen retrieval), rabbit anti-EGFR (Roche, #790-4347, prediluted, 
CC1 antigen retrieval), mouse anti-p16 (Roche, #805-4713, prediluted, CC1 antigen retrieval), 
mouse anti-SFTPA (Abcam, ab51891, 1:200, CC2 antigen retrieval). Hematoxylin-and-eosin 
and immunohistochemical images were taken using a Pannoramic SCAN 150 slide scanner 
(3DHISTECH). 
Panel sequencing 
For panel sequencing of oncogenic mutations and gene fusions, tumor-enriched areas were 
macrodissected from formalin-fixed and paraffin-embedded tissue sections.  
DNA was isolated using the Maxwell RSC DNA FFPE Kit (Promega) on a Maxwell RSC 48 
Instrument (Promega). Isolated DNA was analyzed for oncogenic mutations using the nNGM 
panel v1 (ThermoFisher), an Ion 530 chip (ThermoFisher) and the Ion Chef/Ion S5 XL System 
(ThermoFisher).  
RNA was isolated using the Maxwell RSC RNA FFPE Kit (Promega) on a Maxwell RSC 48 
Instrument (Promega). Isolated RNA was analyzed for oncogenic gene fusions using the 
Oncomine Focus RNA Assay (ThermoFisher), an Ion 530 chip and the Ion Chef/Ion S5 XL 
System (ThermoFisher). 
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The Sequence Pilot Software (Version 4.4.0, JSI Medical Systems) and the Ion Reporter 
Software (Version 5.12, ThermoFisher) were used for variant calling. 
Single-cell RNA sequencing data analysis 
Preprocessing, filtering and normalization 
For each sample, UMIs were quantified using Cellranger 3.0.2 (10x Genomics) with reference 
transcriptome GRCh38. Subsequent analyses were performed using the R package “Seurat 
v3” [54], if not stated otherwise. Single-cell gene expression data of all patients were merged. 
Quality control filters were set to only include cells with 500-10,000 genes detected, 1,000-
100,000 UMIs counted, fraction of mitochondrial reads <30%, and fraction of hemoglobin reads 
<5%. After filtering, UMI counts were variance-stabilized using scTransform with 3,000 variable 
features [55], while regressing out number of UMIs counted and fraction of mitochondrial reads. 
Clustering and cell type annotation 
The top 15 principal components were used to construct shared nearest neighbor (SNN) graph 
and UMAP embedding as implemented in the R package “Seurat v3” with default parameters. 
Next, main cell types (epithelial, immune, stromal) were identified by scoring cell type markers 
across clusters (resolution = 0.2, otherwise default parameters). PCA, SNN graph construction 
and UMAP embedding was rerun on each subset using the top 20 principal components, and 
a resolution of 1 for the epithelial and stromal subsets, or 0.5 for the immune subset with 
otherwise default parameters. Cell type markers used to score epithelial, immune, and stromal 
cell types were adapted from Habermann et al. [56] and Tata et al. [57]. Cell type signatures 
from Vieira Braga et al. [13] and Travaglini et al. [14] were used to validate manual cell type 
annotation. Epithelial or immune contaminated clusters were identified by expression of 
EPCAM or PTPRC, respectively, and removed prior to further analyses. In the epithelial 
subset, cell clusters which were relatively overrepresented in the tumor tissue samples were 
annotated as tumor cells. 
Differential gene expression analysis 
For differential gene expression analysis of epithelial cells, tumor cells from tumor samples 
were subset and gene expression rescaled. Immune and stromal subsets were split as stated, 
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and gene expression rescaled. Marker genes for each cell cluster versus all cells of the subset 
were computed using the FindAllMarkers function of the R package “Seurat v3” with Wilcoxon 
rank-sum test and the following parameters: only positive markers, fraction of expressing cells 
inside the cluster >0.25, difference between fraction of expressing cells inside and outside the 
cluster >0.25, log fold change between cells inside and outside the cluster >0.25. 
Functional analysis 
Cell cycle phases were scores as implemented in the R package “Seurat v3”. Expression of 
gene sets of the Hallmark signature collection of the Broad Institute [22], and M1 vs. M2 up- 
and downregulated genes [23] were scored using the AddModuleScore function of the R 
package “Seurat v3”. Oncogenic signaling pathway activity scores were computed using the R 
package “progeny” [15, 16]. 
TCGA gene expression analysis 
FPKM-normalized gene expression values from RNA sequencing and clinical data of the lung 
adenocarcinoma (LUAD) cohort of The Cancer Genome Project was downloaded using the R 
package “TCGAbiolinks” [58] and log2 transformed. 
Data from single-cell RNA sequencing was subset into myeloid, lymphoid, endothelial and 
stromal compartments, rescaled using the ScaleData function and marker genes identified 
using the FindAllMarkers function (only positive genes, fraction of expressing cells ≥ 0.25, 
difference of fraction of expressing cells ≥ 0.25).  
For epithelial marker genes, tumor-specific clusters in tumor samples were subset, rescaled 
using the ScaleData function and dimensionality reduction performed using RunPCA. The top 
30 genes positively or negatively correlated with principal component 1 were selected for the 
PC1pos or PC1neg marker gene list, respectively. 
Marker gene lists from myeloid, lymphoid, endothelial, stromal and epithelial cell subsets were 
used as gene sets to perform single-sample gene set enrichment analysis (ssGSEA) [26] on 
TCGA LUAD gene expression data using the R package “GSVA” [59] assuming Gaussian 
distribution. 
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Associations between enrichment scores (ES) from ssGSEA were calculated by Pearson 
correlation test using the R package “corrplot”.  
TCGA survival analysis 
For survival analyses, ES from ssGSEA of the TCGA LUAD gene expression data were 
dichotomized (ES > median or ≤ median). For dichotomization of combined enrichment scores, 
the enrichment score matrix was rotated clockwise by the arctangent of the slope from linear 
regression using a rotation matrix and subsequently dichotomized (x value > median or ≤ 
median). 
For survival analysis, survival curves, log rank statistics and Cox regression were calculated 
including the parameters “vital status”, “days to death” and “days to last follow up” from the 
TCGA dataset using the R packages “survival” and “survminer”.  
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 




The work was in part funded by the Berlin Institute of Health (to PB, PJ, DH, MM, CS and NB), 
and the German Cancer Consortium DKTK (to MM and NB). 
PB is participant in the BIH-Charité Junior Clinician Scientist Program funded by the Charité -
Universitätsmedizin Berlin and the Berlin Institute of Health. 
PJ is participant in the BIH-Charité Digital Clinician Scientist Program funded by the Charité -
Universitätsmedizin Berlin and the Berlin Institute of Health and the German Research 
Foundation (DFG). 
Author contributions 
NB, FK, PB conceived and designed the study; 
PB, AT, FK, DH, AE, TD, JN, JR contributed to clinical sample acquisition and preparation;  
AT, PB conducted experiments;  
PB, BO, JP, DB, NB performed bioinformatic analyses;  
PB, FK, NB, PJ, CF, DH, MM, CS analyzed and interpreted data and/or supervised parts of 
the study;  
PB wrote the manuscript;  
FK, NB revised the manuscript; 
all authors provided critical feedback and helped shaping the research, analysis, and 
manuscript.  
Competing Interests 
The authors declare no competing interest. 
Acknowledgement 
We thank Manuela Pacyna-Gengelbach and Barabara Meyer-Bartell for excellent technical 
assistance. 
The results of this study are in part based upon data generated by the TCGA Research 
Network: https://www.cancer.gov/tcga. 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 




1. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and 
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): p. 
394-424. 
2. Wakelee, H.A., et al., Lung cancer incidence in never smokers. J Clin Oncol, 2007. 
25(5): p. 472-8. 
3. Cancer Genome Atlas Research, N., Comprehensive molecular profiling of lung 
adenocarcinoma. Nature, 2014. 511(7511): p. 543-50. 
4. Hirsch, F.R., et al., Lung cancer: current therapies and new targeted treatments. 
Lancet, 2017. 389(10066): p. 299-311. 
5. Memon, H. and B.M. Patel, Immune checkpoint inhibitors in non-small cell lung cancer: 
A bird's eye view. Life Sci, 2019. 233: p. 116713. 
6. Altorki, N.K., et al., The lung microenvironment: an important regulator of tumour growth 
and metastasis. Nat Rev Cancer, 2019. 19(1): p. 9-31. 
7. Lavin, Y., et al., Innate Immune Landscape in Early Lung Adenocarcinoma by Paired 
Single-Cell Analyses. Cell, 2017. 169(4): p. 750-765 e17. 
8. Lambrechts, D., et al., Phenotype molding of stromal cells in the lung tumor 
microenvironment. Nat Med, 2018. 24(8): p. 1277-1289. 
9. Kim, N., et al., Single-cell RNA sequencing demonstrates the molecular and cellular 
reprogramming of metastatic lung adenocarcinoma. Nat Commun, 2020. 11(1): p. 
2285. 
10. Guo, X., et al., Global characterization of T cells in non-small-cell lung cancer by single-
cell sequencing. Nat Med, 2018. 24(7): p. 978-985. 
11. Becht, E., et al., Dimensionality reduction for visualizing single-cell data using UMAP. 
Nat Biotechnol, 2018. 
12. Lee, H.O., et al., Lineage-dependent gene expression programs influence the immune 
landscape of colorectal cancer. Nat Genet, 2020. 
13. Vieira Braga, F.A., et al., A cellular census of human lungs identifies novel cell states 
in health and in asthma. Nat Med, 2019. 25(7): p. 1153-1163. 
14. Travaglini, K.J., et al., A molecular cell atlas of the human lung from single-cell RNA 
sequencing. Nature, 2020. 
15. Schubert, M., et al., Perturbation-response genes reveal signaling footprints in cancer 
gene expression. Nat Commun, 2018. 9(1): p. 20. 
16. Holland, C.H., et al., Robustness and applicability of transcription factor and pathway 
analysis tools on single-cell RNA-seq data. Genome Biol, 2020. 21(1): p. 36. 
17. Naizhen, X., et al., Spatiotemporal Expression of Three Secretoglobin Proteins, 
SCGB1A1, SCGB3A1, and SCGB3A2, in Mouse Airway Epithelia. J Histochem 
Cytochem, 2019. 67(6): p. 453-463. 
18. Yoshida, G.J., Regulation of heterogeneous cancer-associated fibroblasts: the 
molecular pathology of activated signaling pathways. J Exp Clin Cancer Res, 2020. 
39(1): p. 112. 
19. Petrova, V., et al., The hypoxic tumour microenvironment. Oncogenesis, 2018. 7(1): p. 
10. 
20. Franklin, R.A. and M.O. Li, Ontogeny of Tumor-associated Macrophages and Its 
Implication in Cancer Regulation. Trends Cancer, 2016. 2(1): p. 20-34. 
21. Solberg, R., et al., Legumain expression, activity and secretion are increased during 
monocyte-to-macrophage differentiation and inhibited by atorvastatin. Biol Chem, 
2015. 396(1): p. 71-80. 
22. Liberzon, A., et al., The Molecular Signatures Database (MSigDB) hallmark gene set 
collection. Cell Syst, 2015. 1(6): p. 417-425. 
23. Martinez, F.O., et al., Transcriptional profiling of the human monocyte-to-macrophage 
differentiation and polarization: new molecules and patterns of gene expression. J 
Immunol, 2006. 177(10): p. 7303-11. 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.11.419606doi: bioRxiv preprint 
30 
 
24. Solinas, G., et al., Tumor-conditioned macrophages secrete migration-stimulating 
factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol, 
2010. 185(1): p. 642-52. 
25. Jiang, Y., Y. Li, and B. Zhu, T-cell exhaustion in the tumor microenvironment. Cell 
Death Dis, 2015. 6: p. e1792. 
26. Barbie, D.A., et al., Systematic RNA interference reveals that oncogenic KRAS-driven 
cancers require TBK1. Nature, 2009. 462(7269): p. 108-12. 
27. Travis, W.D., et al., The 2015 World Health Organization Classification of Lung Tumors: 
Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J 
Thorac Oncol, 2015. 10(9): p. 1243-1260. 
28. Moreira, A.L., et al., A Grading System for Invasive Pulmonary Adenocarcinoma: A 
Proposal From the International Association for the Study of Lung Cancer Pathology 
Committee. J Thorac Oncol, 2020. 15(10): p. 1599-1610. 
29. Conway, E.M., et al., Macrophages, Inflammation, and Lung Cancer. Am J Respir Crit 
Care Med, 2016. 193(2): p. 116-30. 
30. Ito, M., et al., Prognostic impact of cancer-associated stromal cells in patients with 
stage I lung adenocarcinoma. Chest, 2012. 142(1): p. 151-158. 
31. Koucky, V., J. Boucek, and A. Fialova, Immunology of Plasmacytoid Dendritic Cells in 
Solid Tumors: A Brief Review. Cancers (Basel), 2019. 11(4). 
32. Zhang, S., et al., Prognostic Significance of Tumor-Infiltrating Natural Killer Cells in 
Solid Tumors: A Systematic Review and Meta-Analysis. Front Immunol, 2020. 11: p. 
1242. 
33. Geng, Y., et al., Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a 
Meta-Analysis. Cell Physiol Biochem, 2015. 37(4): p. 1560-71. 
34. Tao, Y., Y. Li, and B. Liang, Comprehensive analysis of microenvironment-related 
genes in lung adenocarcinoma. Future Oncol, 2020. 16(24): p. 1825-1837. 
35. Ojlert, A.K., et al., The immune microenvironment in non-small cell lung cancer is 
predictive of prognosis after surgery. Mol Oncol, 2019. 13(5): p. 1166-1179. 
36. Huang, J., et al., Tumor microenvironment characterization identifies two lung 
adenocarcinoma subtypes with specific immune and metabolic state. Cancer Sci, 2020. 
111(6): p. 1876-1886. 
37. Bironzo, P. and M. Di Maio, A review of guidelines for lung cancer. J Thorac Dis, 2018. 
10(Suppl 13): p. S1556-S1563. 
38. Qu, Y., et al., Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated 
Macrophages Predicts Response to Avelumab Treatment. Cell Rep, 2020. 32(1): p. 
107873. 
39. House, I.G., et al., Macrophage-Derived CXCL9 and CXCL10 Are Required for 
Antitumor Immune Responses Following Immune Checkpoint Blockade. Clin Cancer 
Res, 2020. 26(2): p. 487-504. 
40. Okazaki, T., et al., Periostin is a negative prognostic factor and promotes cancer cell 
proliferation in non-small cell lung cancer. Oncotarget, 2018. 9(58): p. 31187-31199. 
41. Yang, H., et al., Matrix Metalloproteinase 11 Is a Potential Therapeutic Target in Lung 
Adenocarcinoma. Mol Ther Oncolytics, 2019. 14: p. 82-93. 
42. Wrangle, J.M., et al., ALT-803, an IL-15 superagonist, in combination with nivolumab 
in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, 
phase 1b trial. Lancet Oncol, 2018. 19(5): p. 694-704. 
43. Patel, A.J., et al., The role of B lymphocytes in the immuno-biology of non-small-cell 
lung cancer. Cancer Immunol Immunother, 2020. 69(3): p. 325-342. 
44. Alexandrov, L.B., et al., Signatures of mutational processes in human cancer. Nature, 
2013. 500(7463): p. 415-21. 
45. Liu, Y., et al., Genomic heterogeneity of multiple synchronous lung cancer. Nat 
Commun, 2016. 7: p. 13200. 
46. Niemira, M., et al., Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by 
Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by 
Weighted Gene Co-Expression Network Analysis (WGCNA). Cancers (Basel), 2019. 
12(1). 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.11.419606doi: bioRxiv preprint 
31 
 
47. Molina-Romero, C., et al., Differential gene expression profiles according to the 
Association for the Study of Lung Cancer/American Thoracic Society/European 
Respiratory Society histopathological classification in lung adenocarcinoma subtypes. 
Hum Pathol, 2017. 66: p. 188-199. 
48. Mohrherr, J., et al., JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma 
progression. Int J Cancer, 2019. 145(12): p. 3376-3388. 
49. Tan, A.C., Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer 
(NSCLC). Thorac Cancer, 2020. 11(3): p. 511-518. 
50. Stahl, P.L., et al., Visualization and analysis of gene expression in tissue sections by 
spatial transcriptomics. Science, 2016. 353(6294): p. 78-82. 
51. Stoeckius, M., et al., Simultaneous epitope and transcriptome measurement in single 
cells. Nat Methods, 2017. 14(9): p. 865-868. 
52. Buenrostro, J.D., et al., Single-cell chromatin accessibility reveals principles of 
regulatory variation. Nature, 2015. 523(7561): p. 486-90. 
53. Rajewsky, N., et al., LifeTime and improving European healthcare through cell-based 
interceptive medicine. Nature, 2020. 
54. Stuart, T., et al., Comprehensive Integration of Single-Cell Data. Cell, 2019. 177(7): p. 
1888-1902 e21. 
55. Hafemeister, C. and R. Satija, Normalization and variance stabilization of single-cell 
RNA-seq data using regularized negative binomial regression. Genome Biol, 2019. 
20(1): p. 296. 
56. Habermann, A.C., et al., Single-cell RNA sequencing reveals profibrotic roles of distinct 
epithelial and mesenchymal lineages in pulmonary fibrosis. Sci Adv, 2020. 6(28): p. 
eaba1972. 
57. Tata, P.R. and J. Rajagopal, Plasticity in the lung: making and breaking cell identity. 
Development, 2017. 144(5): p. 755-766. 
58. Colaprico, A., et al., TCGAbiolinks: an R/Bioconductor package for integrative analysis 
of TCGA data. Nucleic Acids Res, 2016. 44(8): p. e71. 
59. Hanzelmann, S., R. Castelo, and J. Guinney, GSVA: gene set variation analysis for 
microarray and RNA-seq data. BMC Bioinformatics, 2013. 14: p. 7. 
 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.11.419606doi: bioRxiv preprint 
